Physician profile
Eric M Wolfson
NPI 1023044773
$9,445.44
in general payments reported to CMS, 2019-2025
70 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $583 · 2021: $1,245 · 2022: $1,603 · 2023: $1,739 · 2024: $1,620 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,882 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,881.80 |
| Education | $226.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,500.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $981.05 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $808.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $709.92 | 2019-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $501.78 | 2021-2025 | |
| Abbott Laboratories | $379.00 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $344.73 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $336.49 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $291.55 | 2020-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $284.24 | 2019-2023 | Steglatro, Belsomra, Januvia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250.88 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.15 | 2021-2025 | Jardiance |
| Mannkind Corporation | $199.40 | 2019-2025 | |
| Gilead Sciences, INC. | $188.32 | 2022-2025 | |
| Pfizer INC. | $161.28 | 2022-2025 |
Show all 69 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.